Tirzepatide vs Dulaglutide for Type 2 Diabetes
(SURPASS-CVOT Trial)

Recruiting in Palo Alto (17 mi)

+1210 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Eli Lilly and Company

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for adults with type 2 diabetes who are overweight (BMI ≥25 kg/m²) and have a history of heart disease. They should have an HbA1c level between 7.0% to ≤10.5%. People with plans for certain eye treatments, gastric surgeries, or those with type 1 diabetes, recent severe blood loss, pancreatitis, or major cardiovascular events in the last two months cannot join.

Inclusion Criteria

I have been diagnosed with type 2 diabetes.

I have been diagnosed with heart disease caused by hardened arteries.

You are considered overweight based on your height and weight.

See 1 more

Exclusion Criteria

I have a known issue with my stomach emptying or have had/planning stomach surgery.

I or my family have a history of MTC or MEN-2.

I have not had a blood transfusion or severe blood loss in the last 3 months.

See 8 more

Treatment Details

Interventions

Dulaglutide (Glucagon-like peptide-1 receptor agonist)
Tirzepatide (Glucagon-like peptide-1 receptor agonist)

Trial OverviewThe study compares Tirzepatide (LY3298176) to Dulaglutide in reducing heart-related issues in people with type 2 diabetes at increased risk of cardiovascular events. It aims to see which drug is more effective and safe.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: TirzepatideExperimental Treatment1 Intervention

Tirzepatide administered subcutaneously (SC) once a week.

Group II: DulaglutideActive Control1 Intervention

Dulaglutide administered SC once a week.